Taiho’s Colorectal Cancer Candidate Soars in Phase 3

Taiho Pharmaceutical’s oral combination candidate TAS-102 met primary endpoints in a Phase 3 study in patients with refractory metastatic colorectal cancer.

In a randomized, double-blind, placebo-controlled Phase 3 trial in 406 patients, the therapy demonstrated improvement in overall survival for patients whose refractory mCRC had progressed after standard treatment. The study was conducted in China, South Korea and Thailand.